18F‐Fluorocholine PET/CT in prostate cancer initial staging

Detalhes bibliográficos
Autor(a) principal: Lapa, Paula
Data de Publicação: 2017
Outros Autores: Silva, Rodolfo, Saraiva, Tiago, Figueiredo, Arnaldo, Ferreira, Rui, Costa, Gracinda, Pedroso Lima, João
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.24915/aup.33.3.34
Resumo: AimIn the evaluation of prostate cancer, clinical nomograms are commonly used to predict the probability of lymphatic and extra‐nodal spread. Those nomograms may suggest the presence and the extension of this cancer but do not allow a clear distinction between loco‐regional and distant disease. In this study, it was intended to evaluate the usefulness of 18F‐Fluorocoline positron emission tomography/computed tomography (18F‐FCH‐PET/CT) in the workup of patients with the initial diagnosis of prostate cancer and staged by this imaging technique.Material and methodsThe medical records of 39 patients with prostate cancer who underwent 18F‐FCH PET/CT for initial staging, between November 2010 and April 2015, were reviewed. Of these, 20 patients were excluded because they had already started hormonotherapy. In the other 19 patients, the performance of 18F‐FCH PET/CT for the detection of lymph node metastasis was evaluated by calculating the sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy. Six patients had performed pelvic lymphadenectomy (total of 69 lymph nodes), allowing histological confirmation. When there was no histological confirmation (total of 30 lymph nodes and 3 cases of bone metastasis), the findings of 18F‐FCH PET/CT were correlated with the values of PSA and the information from multiple imaging modalities such as CT, bone scan, magnetic resonance (MRI), 18F‐Sodium Fluoride (18F‐NaF) PET/CT of control.ResultsThe sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy for lymph node metastasis detection were, respectively, 96.8%, 80.9%, 69.8%, 98.2% and 85.8%. In our sample, this technique also allowed the identification of nodal extra pelvic or bone metastasis in 5 patients (26.3%) with implications in the treatment. It showed uptake suggestive of bone metastasis, corroborated by other diagnostic technics or by the follow‐up, in 3 patients, those with prostate specific antigen (PSA) of 9.5±2.9 ng/mL.Conclusion18F‐FCH PET/CT is an entire body and multi organ imaging modality that allows the identification, globally, of the sites of disease in patients with prostate cancer. In this study, 18F‐FCH PET/CT showed good results when used in the initial staging of these patients. It is highlighted the ability to detect distant disease, in particular bone metastasis, even with PSA<20ng/mL.
id RCAP_7aea83b50e51718f86826cbf86c64321
oai_identifier_str oai:oai.actaurologicaportuguesa.com:article/34
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling 18F‐Fluorocholine PET/CT in prostate cancer initial stagingPET/CT com Fluorocolina‐F18 no estadiamento inicial do carcinoma da próstataFluorocholineProstatic NeoplasmsRadiopharmaceuticalsPositron‐Emission TomographyFluorocolinaNeoplasias da próstataRadiofármacosTomografia por emissão de positrõesAimIn the evaluation of prostate cancer, clinical nomograms are commonly used to predict the probability of lymphatic and extra‐nodal spread. Those nomograms may suggest the presence and the extension of this cancer but do not allow a clear distinction between loco‐regional and distant disease. In this study, it was intended to evaluate the usefulness of 18F‐Fluorocoline positron emission tomography/computed tomography (18F‐FCH‐PET/CT) in the workup of patients with the initial diagnosis of prostate cancer and staged by this imaging technique.Material and methodsThe medical records of 39 patients with prostate cancer who underwent 18F‐FCH PET/CT for initial staging, between November 2010 and April 2015, were reviewed. Of these, 20 patients were excluded because they had already started hormonotherapy. In the other 19 patients, the performance of 18F‐FCH PET/CT for the detection of lymph node metastasis was evaluated by calculating the sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy. Six patients had performed pelvic lymphadenectomy (total of 69 lymph nodes), allowing histological confirmation. When there was no histological confirmation (total of 30 lymph nodes and 3 cases of bone metastasis), the findings of 18F‐FCH PET/CT were correlated with the values of PSA and the information from multiple imaging modalities such as CT, bone scan, magnetic resonance (MRI), 18F‐Sodium Fluoride (18F‐NaF) PET/CT of control.ResultsThe sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy for lymph node metastasis detection were, respectively, 96.8%, 80.9%, 69.8%, 98.2% and 85.8%. In our sample, this technique also allowed the identification of nodal extra pelvic or bone metastasis in 5 patients (26.3%) with implications in the treatment. It showed uptake suggestive of bone metastasis, corroborated by other diagnostic technics or by the follow‐up, in 3 patients, those with prostate specific antigen (PSA) of 9.5±2.9 ng/mL.Conclusion18F‐FCH PET/CT is an entire body and multi organ imaging modality that allows the identification, globally, of the sites of disease in patients with prostate cancer. In this study, 18F‐FCH PET/CT showed good results when used in the initial staging of these patients. It is highlighted the ability to detect distant disease, in particular bone metastasis, even with PSA<20ng/mL.ObjetivoNa avaliação do carcinoma da próstata são habitualmente utilizados nomogramas clínicos para prever a probabilidade de disseminação linfática e extra ganglionar. Esses nomogramas podem sugerir a presença e a extensão desta neoplasia, mas não permitem a distinção clara entre doença loco regional e à distância. Pretendeu‐se, com este trabalho, avaliar a utilidade da tomografia por emissão de positrões/tomografia computorizada (PET/CT) com Fluorocolina‐F18 (FCH‐F18) na orientação de doentes com o diagnóstico inicial de carcinoma da próstata e estadiados por esta técnica imagiológica.Material e métodosForam revistos os processos clínicos de 39 doentes com carcinoma da próstata que realizaram PET/CT com FCH‐F18 para estadiamento inicial, entre novembro de 2010 e abril de 2015. Destes, 20 doentes foram excluídos por terem iniciado hormonoterapia. Nos restantes 19 doentes, foi avaliado o desempenho da PET/CT com FCH‐F18 para deteção de metastização ganglionar através do cálculo dos valores de sensibilidade, especificidade, valor preditivo positivo, valor preditivo negativo e acuidade diagnóstica. Seis doentes realizaram linfadenectomia pélvica (total de 69 gânglios), permitindo confirmação histológica. Quando não existia confirmação histológica, os achados da PET/CT com FCH‐F18 (total de 30 gânglios e 3 casos de metastização óssea) foram correlacionados com os valores do antigénio prostático específico (PSA) e com as informações de várias modalidades imagiológicas, como CT, cintigrafia óssea, ressonância magnética (RM), PET/CT com Fluoreto de Sódio‐F18 (FNa‐F18) e PET/CT com FCH‐F18 de controlo.ResultadosOs valores de sensibilidade, especificidade, valor preditivo positivo, valor preditivo negativo e acuidade diagnóstica para deteção de metastização ganglionar foram, respetivamente, 96,8%, 80,9%, 69,8%, 98,2% e 85,8%. Na nossa amostra, esta técnica identificou metástases, ganglionares extrapélvicas ou ósseas em 5 doentes (26,3%) com implicações na abordagem terapêutica. Mostrou captação sugestiva de metastização óssea, corroborada por outros meios de diagnóstico e pelo seguimento, em 3 doentes, estes com PSA de 9,5±2,9ng/mL.ConclusõesA PET/CT com FCH‐F18 é uma modalidade imagiológica de corpo inteiro e multiorgão que permite identificar, de modo global, os locais de doença, em doentes com carcinoma da próstata. Neste estudo, a PET/CT com FCH‐F18 apresentou bons resultados quando utilizada no processo de estadiamento inicial destes doentes. Salienta‐se a sua capacidade para deteção de doença à distância, nomeadamente óssea, mesmo com PSA<20ng/mL.Associação Portuguesa de Urologia2017-04-10T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.24915/aup.33.3.34oai:oai.actaurologicaportuguesa.com:article/34Acta Urológica Portuguesa; Vol. 33 No. 3 (2016): Setembro-Dezembro; 87-97Acta Urológica Portuguesa; v. 33 n. 3 (2016): Setembro-Dezembro; 87-972387-04192341-4022reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttp://www.actaurologicaportuguesa.com/index.php/aup/article/view/34https://doi.org/10.24915/aup.33.3.34http://www.actaurologicaportuguesa.com/index.php/aup/article/view/34/4Lapa, PaulaSilva, RodolfoSaraiva, TiagoFigueiredo, ArnaldoFerreira, RuiCosta, GracindaPedroso Lima, Joãoinfo:eu-repo/semantics/openAccess2022-09-21T09:04:45Zoai:oai.actaurologicaportuguesa.com:article/34Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:55:52.507006Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv 18F‐Fluorocholine PET/CT in prostate cancer initial staging
PET/CT com Fluorocolina‐F18 no estadiamento inicial do carcinoma da próstata
title 18F‐Fluorocholine PET/CT in prostate cancer initial staging
spellingShingle 18F‐Fluorocholine PET/CT in prostate cancer initial staging
Lapa, Paula
Fluorocholine
Prostatic Neoplasms
Radiopharmaceuticals
Positron‐Emission Tomography
Fluorocolina
Neoplasias da próstata
Radiofármacos
Tomografia por emissão de positrões
title_short 18F‐Fluorocholine PET/CT in prostate cancer initial staging
title_full 18F‐Fluorocholine PET/CT in prostate cancer initial staging
title_fullStr 18F‐Fluorocholine PET/CT in prostate cancer initial staging
title_full_unstemmed 18F‐Fluorocholine PET/CT in prostate cancer initial staging
title_sort 18F‐Fluorocholine PET/CT in prostate cancer initial staging
author Lapa, Paula
author_facet Lapa, Paula
Silva, Rodolfo
Saraiva, Tiago
Figueiredo, Arnaldo
Ferreira, Rui
Costa, Gracinda
Pedroso Lima, João
author_role author
author2 Silva, Rodolfo
Saraiva, Tiago
Figueiredo, Arnaldo
Ferreira, Rui
Costa, Gracinda
Pedroso Lima, João
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Lapa, Paula
Silva, Rodolfo
Saraiva, Tiago
Figueiredo, Arnaldo
Ferreira, Rui
Costa, Gracinda
Pedroso Lima, João
dc.subject.por.fl_str_mv Fluorocholine
Prostatic Neoplasms
Radiopharmaceuticals
Positron‐Emission Tomography
Fluorocolina
Neoplasias da próstata
Radiofármacos
Tomografia por emissão de positrões
topic Fluorocholine
Prostatic Neoplasms
Radiopharmaceuticals
Positron‐Emission Tomography
Fluorocolina
Neoplasias da próstata
Radiofármacos
Tomografia por emissão de positrões
description AimIn the evaluation of prostate cancer, clinical nomograms are commonly used to predict the probability of lymphatic and extra‐nodal spread. Those nomograms may suggest the presence and the extension of this cancer but do not allow a clear distinction between loco‐regional and distant disease. In this study, it was intended to evaluate the usefulness of 18F‐Fluorocoline positron emission tomography/computed tomography (18F‐FCH‐PET/CT) in the workup of patients with the initial diagnosis of prostate cancer and staged by this imaging technique.Material and methodsThe medical records of 39 patients with prostate cancer who underwent 18F‐FCH PET/CT for initial staging, between November 2010 and April 2015, were reviewed. Of these, 20 patients were excluded because they had already started hormonotherapy. In the other 19 patients, the performance of 18F‐FCH PET/CT for the detection of lymph node metastasis was evaluated by calculating the sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy. Six patients had performed pelvic lymphadenectomy (total of 69 lymph nodes), allowing histological confirmation. When there was no histological confirmation (total of 30 lymph nodes and 3 cases of bone metastasis), the findings of 18F‐FCH PET/CT were correlated with the values of PSA and the information from multiple imaging modalities such as CT, bone scan, magnetic resonance (MRI), 18F‐Sodium Fluoride (18F‐NaF) PET/CT of control.ResultsThe sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy for lymph node metastasis detection were, respectively, 96.8%, 80.9%, 69.8%, 98.2% and 85.8%. In our sample, this technique also allowed the identification of nodal extra pelvic or bone metastasis in 5 patients (26.3%) with implications in the treatment. It showed uptake suggestive of bone metastasis, corroborated by other diagnostic technics or by the follow‐up, in 3 patients, those with prostate specific antigen (PSA) of 9.5±2.9 ng/mL.Conclusion18F‐FCH PET/CT is an entire body and multi organ imaging modality that allows the identification, globally, of the sites of disease in patients with prostate cancer. In this study, 18F‐FCH PET/CT showed good results when used in the initial staging of these patients. It is highlighted the ability to detect distant disease, in particular bone metastasis, even with PSA<20ng/mL.
publishDate 2017
dc.date.none.fl_str_mv 2017-04-10T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.24915/aup.33.3.34
oai:oai.actaurologicaportuguesa.com:article/34
url https://doi.org/10.24915/aup.33.3.34
identifier_str_mv oai:oai.actaurologicaportuguesa.com:article/34
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv http://www.actaurologicaportuguesa.com/index.php/aup/article/view/34
https://doi.org/10.24915/aup.33.3.34
http://www.actaurologicaportuguesa.com/index.php/aup/article/view/34/4
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Associação Portuguesa de Urologia
publisher.none.fl_str_mv Associação Portuguesa de Urologia
dc.source.none.fl_str_mv Acta Urológica Portuguesa; Vol. 33 No. 3 (2016): Setembro-Dezembro; 87-97
Acta Urológica Portuguesa; v. 33 n. 3 (2016): Setembro-Dezembro; 87-97
2387-0419
2341-4022
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130427642871808